|
Ortiz-Fernandez P, Iniesta-Navalon C, Urbieta-Sanz E, Gascon-Canovas JJ. Assessing early therapeutic drug monitoring of adalimumab as a predictor of treatment efficacy and immunogenicity in rheumatic diseases. Clin Rheumatol. 2025 Aug;44(8):3389-3390. doi: 10.1007/s10067-025-07559-w. Epub 2025 Jul 4. No abstract available. PubMed PMID: 40613968.
AÑO: 2025; IF: 2.9
|
40613968
|
Iniesta-Navalon C, Rios-Saorin M, Anez-Castano R, Rentero-Redondo L, Ortiz-Fernandez P, Marin-Armero Martinez E, Urbieta-Sanz E. Evaluating the Accuracy and Clinical Utility of AFIAS-10 Point of Care Versus Enzyme-Linked Immunosorbent Assay in Therapeutic Drug Monitoring of Infliximab and Adalimumab. Ther Drug Monit. 2025 Jun 1;47(3):346-352. doi: 10.1097/FTD.0000000000001269. Epub 2024 Nov 15. PubMed PMID: 40341590.
AÑO: 2025; IF: 2.8
|
|
Iniesta Navalon C, Rios-Saorin M, Rentero-Redondo L, Nicolas-de Prado I, Gomez-Espin R, Urbieta Sanz E. Impact of ustekinumab exposure on clinical outcomes during induction in inflammatory bowel disease. Rev Esp Enferm Dig. 2024 Dec 4. doi: 10.17235/reed.2024.10521/2024. Online ahead of print. PubMed PMID: 39629805.
AÑO: 2024; IF: 2.7
|
|
Iniesta-Navalon C, Rios-Saorin M, Rentero-Redondo L, Anez-Castano R, Urbieta-Sanz E. Comparative evaluation of point of care assay with ELISA techniques for quantifying serum concentrations of ustekinumab in inflammatory bowel disease patients. Gastroenterol Hepatol. 2024 Oct 21:S0210-5705(24)00284-X. doi: 10.1016/j.gastrohep.2024.502277. Online ahead of print. English, Spanish. PubMed PMID: 39442691.
AÑO: 2024; IF: 2.2
|
|
Díaz L.S., Navalón C.I., Espín R.G., de Prado I.N., Morell E.B., Redondo L.R. Impact of proactive therapeutic drug monitoring of infliximab during the induction phase in IBD patients. A Bayesian approach. Revista Espanola de Enfermedades Digestivas. 2023. 115:435-443. 10.17235/reed.2022.8781/2022
AÑO: 2023; IF: 2.7
|